Puma Biotechnology Inc. Revenue 2017–2025
Puma Biotechnology Inc. annual/quarterly revenue history and growth rate from 2017 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Puma Biotechnology Inc. revenue for the quarter ending March 31, 2026 was 44.8 M, a 2.59% decrease year-over-year.
- Puma Biotechnology Inc. revenue for the twelve months ending March 31, 2026 was 197.7 M, a 13.09% decrease year-over-year.
- Puma Biotechnology Inc. annual revenue for 2025 was 228.4 M, a 0.91% decrease from 2024.
- Puma Biotechnology Inc. annual revenue for 2024 was 230.5 M, a 2.19% decrease from 2023.
- Puma Biotechnology Inc. annual revenue for 2023 was 235.6 M, a 3.34% increase from 2022.
- Puma Biotechnology Inc. annual revenue for 2022 was 228.0 M.
Puma Biotechnology Inc. (PBYI) — Frequently Asked Questions
Puma Biotechnology Inc. (PBYI) is a publicly traded US company. It has a market capitalization of $356M. In fiscal 2025 it reported revenue of $228M and net income of $31M. Explore PBYI's stock price, financial statements, earnings history, margins and key ratios below.
What is Puma Biotechnology Inc.'s market cap?
Puma Biotechnology Inc. (PBYI) has a market capitalization of $356M.
What is the PBYI stock price?
PBYI trades at $7.02 (-0.43% on the day).
How much revenue does Puma Biotechnology Inc. make?
Puma Biotechnology Inc. reported revenue of $228M in fiscal 2025.
Is PBYI profitable?
In fiscal 2025, Puma Biotechnology Inc. reported net income of $31M.